Hyperliquid to Raise $1B via Chardan Equity Facility Post-Merger

TL;DR

**PURR is setting up a massive $1 billion ATM facility with Chardan, signaling a potential cash injection but also significant dilution risk post-merger with Sonnet and Rorschach.**

AI Summary

Hyperliquid Strategies Inc (PURR) filed an S-1 on October 22, 2025, detailing a proposed business combination with Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC. The filing outlines a committed equity facility (ChEF) with Chardan Capital Markets LLC, allowing Hyperliquid to sell up to 160,000,000 shares of common stock to Chardan. Hyperliquid expects to receive up to $1.0 billion in aggregate gross proceeds from this facility, which will be used for general corporate purposes, including potential purchases of HYPE Tokens, following the consummation of the Business Combination. The company will pay Chardan a commitment fee totaling $1.0 million, consisting of $125,000 at commencement, $250,000 upon receiving $25.0 million in proceeds, and $625,000 upon receiving $50.0 million in proceeds, in addition to a $25,000 documentation fee. The offering of these shares is contingent upon the closing of the Business Combination, which includes the Rorschach Merger and the Company Merger. Hyperliquid has applied to list its common stock on the Nasdaq Capital Market under the symbol "PURR" and expects to be an "emerging growth company" and a "smaller reporting company."

Why It Matters

This S-1 filing is crucial for investors as it details Hyperliquid Strategies Inc's plan to raise up to $1.0 billion through a committed equity facility with Chardan Capital Markets LLC, contingent on its business combination with Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC. This financing mechanism, while providing capital, could lead to significant dilution for existing shareholders as up to 160,000,000 shares may be issued. The success of this strategy hinges on the completion of the complex two-step merger and the market's reception of the newly combined entity, which aims to list on Nasdaq under 'PURR'. Competitors in the biotech and financial strategies sectors will be watching closely to see how this substantial capital infusion impacts Hyperliquid's strategic outlook and market positioning.

Risk Assessment

Risk Level: high — The risk level is high due to the offering being conditioned upon the closing of a complex Business Combination involving two mergers (Rorschach Merger and Company Merger), with no assurance that it will be completed. Furthermore, the committed equity facility allows for the issuance of up to 160,000,000 shares, which could lead to substantial dilution for existing shareholders, and the actual proceeds may be less than the stated $1.0 billion depending on market price.

Analyst Insight

Investors should closely monitor the progress of the Business Combination and the market price of PURR's common stock post-listing. Given the potential for significant dilution from the $1.0 billion committed equity facility, a cautious approach is warranted until the combined entity's financial performance and capital deployment strategy become clearer.

Key Numbers

• $1.0B — Maximum aggregate gross proceeds (Expected from the committed equity facility with Chardan Capital Markets LLC)
• 160,000,000 — Maximum shares of common stock (Potentially issued to Chardan Capital Markets LLC under the Purchase Agreement)
• $1.0M — Total Commitment Fee (Payable to Chardan Capital Markets LLC for the committed equity facility)
• $25,000 — Documentation Fee (Paid to Chardan Capital Markets LLC for the Purchase Agreement preparation)
• July 11, 2025 — Date of Business Combination Agreement (Initial agreement date for the merger with Sonnet and Rorschach)
• September 22, 2025 — Date of Business Combination Agreement Amendment (Amendment date for the merger with Sonnet and Rorschach)
• $2.0M — Bridge Financing (Sale of convertible notes by Sonnet BioTherapeutics Holdings, Inc. on June 30, 2025)
• 865,052 — Bridge Financing Warrants (Shares of Company Common Stock convertible into 173,010 shares of Pubco Common Stock at closing)
• 243,787,992 — Closing PIPE shares of Company Common Stock (Issued at $1.25 per share, converting to 48,757,597 shares of Pubco Common Stock)
• 5% — Advisor Shares (Percentage of fully-diluted Pubco Common Stock issued to Rorschach Advisors LLC post-merger)

Key Players & Entities

• Hyperliquid Strategies Inc (company) — Registrant and Pubco
• Sonnet BioTherapeutics Holdings, Inc. (company) — Company being acquired in the Business Combination
• Rorschach I LLC (company) — Company being acquired in the Business Combination
• Chardan Capital Markets LLC (company) — Selling Securityholder and counterparty to the Committed Equity Facility
• David Schamis (person) — Chief Executive Officer of Hyperliquid Strategies Inc
• Alan I. Annex, Esq. (person) — Legal counsel from Greenberg Traurig, LLP
• Jason T. Simon, Esq. (person) — Legal counsel from Greenberg Traurig, LLP
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Nasdaq Capital Market (regulator) — Proposed listing exchange for PURR common stock
• Greenberg Traurig, LLP (company) — Legal counsel for Hyperliquid Strategies Inc

FAQ

Risk Factors

• Committed Equity Financing Risks [medium — financial]: The company has entered into a committed equity facility (ChEF) with Chardan Capital Markets LLC, allowing for the sale of up to 160,000,000 shares of common stock for up to $1.0 billion in aggregate gross proceeds. This facility is contingent upon the closing of the business combination. The company will pay Chardan a total commitment fee of $1.0 million, plus a $25,000 documentation fee.
• Business Combination Contingencies [high — legal]: The offering of shares under the committed equity facility is contingent upon the successful closing of the business combination, which involves a merger with Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC. Delays or failure to close the business combination would impact the ability to utilize the equity financing.
• Nasdaq Listing Uncertainty [medium — market]: Hyperliquid has applied to list its common stock on the Nasdaq Capital Market under the symbol 'PURR'. The listing is subject to meeting Nasdaq's requirements, and there is no guarantee that the listing will be approved or maintained.
• Emerging Growth and Smaller Reporting Company Status [low — regulatory]: The company expects to be classified as an 'emerging growth company' and a 'smaller reporting company'. This status provides certain exemptions from reporting requirements, but also means less stringent disclosure obligations, which could impact investor information.

Industry Context

The S-1 filing pertains to a business combination involving entities in the biotechnology sector, specifically Sonnet BioTherapeutics. This industry is characterized by high research and development costs, long product development cycles, significant regulatory hurdles (FDA approval), and substantial capital requirements. Companies often rely on equity financing, partnerships, and strategic acquisitions to fund operations and advance their pipelines.

Regulatory Implications

As a biotechnology company pursuing a business combination and seeking a Nasdaq listing, Hyperliquid will be subject to SEC regulations and Nasdaq listing rules. Its status as an 'emerging growth company' and 'smaller reporting company' will allow for reduced disclosure requirements, but it must still comply with all applicable securities laws and reporting obligations.

What Investors Should Do

1. Review the terms and conditions of the committed equity facility with Chardan Capital Markets LLC.
2. Analyze the structure and closing conditions of the business combination.
3. Evaluate the financial health and operational plans of Sonnet BioTherapeutics and Rorschach I LLC.
4. Monitor the Nasdaq listing application and approval process.

Key Dates

• 2025-07-11: Business Combination Agreement — Initial agreement for the merger between Hyperliquid, Sonnet BioTherapeutics Holdings, Inc., and Rorschach I LLC.
• 2025-09-22: Business Combination Agreement Amendment — Indicates modifications or updates to the terms of the initial business combination agreement.
• 2025-06-30: Sonnet BioTherapeutics Bridge Financing — Sonnet raised $2.0 million through convertible notes, which may convert into Pubco Common Stock upon closing of the business combination.
• 2025-10-22: S-1 Filing — Hyperliquid Strategies Inc. filed its S-1 registration statement detailing the proposed business combination and equity financing.

Glossary

Committed Equity Facility (ChEF)

An agreement where a company can sell shares of its common stock to an investor (Chardan Capital Markets LLC in this case) at its discretion, up to a specified amount, over a period of time. (Provides Hyperliquid with a potential source of up to $1.0 billion in capital, subject to the closing of the business combination.)

Business Combination

A transaction where two or more companies merge or combine their operations, often involving a SPAC (Special Purpose Acquisition Company) or a similar structure, to form a new or surviving entity. (The core transaction for Hyperliquid, Sonnet BioTherapeutics, and Rorschach I LLC, leading to the creation of the combined entity.)

PIPE Shares

Private Investment in Public Equity. Shares purchased by institutional investors in a private placement, often in connection with a business combination or to raise capital. (243,787,992 PIPE shares were issued at $1.25 per share, converting to 48,757,597 shares of Pubco Common Stock, indicating significant investor commitment.)

Emerging Growth Company

A classification under the JOBS Act for companies with less than $1.235 billion in annual gross revenue, allowing for scaled disclosure requirements. (Hyperliquid expects this status, which may reduce the amount of financial and other information provided to investors.)

Smaller Reporting Company

A company that meets certain revenue and public float thresholds, allowing for reduced SEC filing requirements. (Hyperliquid also expects this status, further simplifying reporting obligations.)

Pubco Common Stock

The common stock of the 'public company' that will result from the business combination. (This is the stock that investors will ultimately hold and trade after the mergers are completed.)

Year-Over-Year Comparison

This is the initial S-1 filing for the proposed business combination, therefore a direct comparison of key financial metrics like revenue growth, margins, or net income to a previous filing is not applicable. The filing focuses on outlining the terms of the business combination, the committed equity financing, and the expected post-merger structure, rather than historical performance of a single operating entity.

Key Financial Figures

• $0.01 — 000,000 shares of Pubco's common stock, $0.01 par value per share (" Common Stock " o
• $1.0 billion — Stock by Chardan. We may receive up to $1.0 billion in aggregate gross proceeds from Charda
• $125,000 — rdan a commitment fee consisting of (i) $125,000 payable on the later of the date of the
• $250,000 — ctive (the " Commencement Date "), (ii) $250,000 payable once we have received an aggreg
• $25.0 million — e once we have received an aggregate of $25.0 million in proceeds from sales of our Common St
• $625,000 — mmon Stock under the Facility and (iii) $625,000 payable once we have received an aggreg
• $50.0 million — e once we have received an aggregate of $50.0 million in proceeds from sales of our Common St
• $25,000 — id Chardan a documentation fee equal to $25,000 (the " Documentation Fee ") as consider
• $2.0 million — " Bridge Financing " means the sale of $2.0 million of convertible notes in the principal a
• $1.25 — any Common Stock at a purchase price of $1.25 per share (which shares will be convert
• $0.0001 — any's common stock, with a par value of $0.0001 per share; " Company In-The-Money War
• $46.372 — Rorschach Merger Effective Time by (b) $46.372. For the avoidance of doubt, if less th
• $200,000,000 — less than Two Hundred Million Dollars ($200,000,000) in HYPE Tokens Value is contributed to
• $5.5 million — al PIPE Warrants, for gross proceeds of $5.5 million; " Initial PIPE Warrants " means thos
• $3,000,000 — by the Company of up to an aggregate of $3,000,000 of its securities as permitted under th

Filing Documents

• forms-1.htm (S-1) — 4360KB
• ex5-1.htm (EX-5.1) — 12KB
• ex10-42.htm (EX-10.42) — 470KB
• ex10-43.htm (EX-10.43) — 158KB
• ex23-1.htm (EX-23.1) — 3KB
• ex23-2.htm (EX-23.2) — 3KB
• ex23-3.htm (EX-23.3) — 4KB
• ex107.htm (EX-FILING FEES) — 32KB
• forms-1_001.jpg (GRAPHIC) — 27KB
• forms-1_002.jpg (GRAPHIC) — 62KB
• forms-1_003.jpg (GRAPHIC) — 28KB
• forms-1_004.jpg (GRAPHIC) — 41KB
• forms-1_005.jpg (GRAPHIC) — 45KB
• forms-1_006.jpg (GRAPHIC) — 40KB
• forms-1_007.jpg (GRAPHIC) — 36KB
• forms-1_008.jpg (GRAPHIC) — 43KB
• forms-1_009.jpg (GRAPHIC) — 45KB
• forms-1_010.jpg (GRAPHIC) — 39KB
• forms-1_011.jpg (GRAPHIC) — 37KB
• forms-1_012.jpg (GRAPHIC) — 136KB
• forms-1_013.jpg (GRAPHIC) — 60KB
• forms-1_014.jpg (GRAPHIC) — 50KB
• ex5-1_001.jpg (GRAPHIC) — 3KB
• 0001493152-25-018936.txt ( ) — 14884KB
• hlsi-20250702.xsd (EX-101.SCH) — 56KB
• hlsi-20250702_cal.xml (EX-101.CAL) — 60KB
• hlsi-20250702_def.xml (EX-101.DEF) — 417KB
• hlsi-20250702_lab.xml (EX-101.LAB) — 406KB
• hlsi-20250702_pre.xml (EX-101.PRE) — 400KB
• forms-1_htm.xml (XML) — 1998KB
• ex107_htm.xml (XML) — 7KB

RISK FACTORS

RISK FACTORS 15 THE COMMITTED EQUITY FINANCING 83

USE OF PROCEEDS

USE OF PROCEEDS 89 DETERMINATION OF OFFERING PRICE 90 MARKET INFORMATION FOR COMMON STOCK 91 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS 92 DESCRIPTION OF PUBCO CAPITAL STOCK 105 INFORMATION ABOUT SONNET 107

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF SONNET

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF SONNET 147 INFORMATION ABOUT RORSCHACH AND PUBCO 164

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF RORSCHACH AND PUBCO

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF RORSCHACH AND PUBCO 181 MANAGEMENT OF PUBCO FOLLOWING THE TRANSACTIONS 183 BENEFICIAL OWNERSHIP OF SECURITIES 192 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 194 SELLING SECURITYHOLDER 195 PLAN OF DISTRIBUTION (CONFLICTS OF INTEREST) 197 WHERE YOU CAN FIND MORE INFORMATION 200 LEGAL MATTERS 200 EXPERTS 200 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS This prospectus is part of a resale registration statement on Form S-1 that we filed with the SEC whereby the Selling Securityholder may, from time to time, sell the securities offered by it described in this prospectus. We will not receive any proceeds from the sale by such Selling Securityholder of the securities offered by it described in this prospectus. Neither we nor the Selling Securityholder has authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholder takes responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholder will make an offer to sell these securities in any jurisdiction where such offer or sale is not permitted. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate as of the date on the front of those documents only, regardless of the time of delivery of this prospectus or any applicable prospectus supplement, or any sale of a security. Our bus

View Full Filing

View this S-1 filing on SEC EDGAR